Vigil Neuroscience, Inc.

NasdaqGS:VIGL Stock Report

Market Cap: US$89.8m

Vigil Neuroscience Management

Management criteria checks 2/4

Vigil Neuroscience's CEO is Ivana Magovcevic-Liebisch, appointed in Jul 2020, has a tenure of 4.33 years. total yearly compensation is $3.85M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $456.91K. The average tenure of the management team and the board of directors is 2.8 years and 3.6 years respectively.

Key information

Ivana Magovcevic-Liebisch

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage15.2%
CEO tenure4.3yrs
CEO ownership0.5%
Management average tenure2.8yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30
We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Sep 16

Vigil Neuroscience announces $75M PIPE financing

Aug 12

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Jul 25
We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Apr 10
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Ivana Magovcevic-Liebisch's remuneration changed compared to Vigil Neuroscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$4mUS$585k

-US$83m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$4mUS$557k

-US$68m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$3mUS$450k

-US$43m

Dec 31 2020US$3mUS$204k

-US$57m

Compensation vs Market: Ivana's total compensation ($USD3.85M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Ivana's compensation has increased whilst the company is unprofitable.

CEO

Ivana Magovcevic-Liebisch (57 yo)

4.3yrs

Tenure

US$3,847,287

Compensation

Dr. Ivana Magovcevic-Liebisch, Ph. D., J. D., serves as a Director of Quanterix Corporation since October 2024. She serves as an Independent Director of Acrivon Therapeutics, Inc. since February 08, 2024....

Leadership Team

NamePositionTenureCompensationOwnership
Ivana Magovcevic-Liebisch
President4.3yrsUS$3.85m0.51%
$ 456.9k
Jennifer Ziolkowski
Chief Financial Officer3.7yrsUS$1.70m0.0098%
$ 8.8k
David Gray
Chief Scientific Officer1.8yrsUS$2.77m0%
$ 0
Sharon Morani
Senior Director of Facilities & Operations1.8yrsno datano data
Eric Brophy
Senior Manager of Information Technologyno datano datano data
Leah Gibson
Vice President of Investor Relations and Corporate Communicationsno datano datano data
April Effort
VP & Head of Corporate Development2.8yrsno datano data
Evan Thackaberry
Senior VP & Head of Early Development4.2yrsno data0.0037%
$ 3.3k
Christian Mirescu
Senior VP & Head of Neuroimmunology2.8yrsno datano data
Weeteck Yeo
Senior Vice President of Strategic Operations2.8yrsno datano data
Jessica Stromme
Senior Vice President of Program Leadership & Portfolio Management2.8yrsno datano data
Ali Toumadj
VP & Head of Medical Sciences1.8yrsno datano data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: VIGL's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ivana Magovcevic-Liebisch
President4.3yrsUS$3.85m0.51%
$ 456.9k
Suzanne Bruhn
Independent Director2.3yrsUS$138.50k0%
$ 0
Cheryl Blanchard
Independent Director4yrsUS$140.00k0%
$ 0
Mary Thistle
Independent Director2.6yrsUS$143.83k0%
$ 0
Ole Isacson
Member of Scientific Advisory Board2.8yrsno datano data
Bruce Booth
Independent Chairman of the Board4.4yrsUS$165.00k0%
$ 0
Marco Colonna
Chairman of Scientific Advisory Boardno datano datano data
Gerhard Koenig
Independent Director4.3yrsUS$136.33k0%
$ 0
Bradley Hyman
Member of Scientific Advisory Boardno datano datano data
Stefan Vitorovic
Independent Director3.3yrsUS$136.83k0.064%
$ 57.4k
Jaime Grutzendler
Member of Scientific Advisory Boardno datano datano data
John Dunlop
Member of Scientific Advisory Boardno datano datano data

3.6yrs

Average Tenure

60.5yo

Average Age

Experienced Board: VIGL's board of directors are considered experienced (3.6 years average tenure).